Cargando…

Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis

This study is aimed at assessing the efficacy and safety of antivascular endothelial growth factor (anti-VEGF) inhibitors in treating age-related macular degeneration (AMD). PubMed, Embase, and Cochrane library were searched. Weighted mean difference (WMD) and relative risk (RR) with 95% confidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Xiaobei, He, Ting, Yang, Shanshan, Cui, Hui, Jiang, Wenlan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033403/ https://www.ncbi.nlm.nih.gov/pubmed/35465351 http://dx.doi.org/10.1155/2022/6004047

Ejemplares similares

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021)

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
por: Tan, Colin S, et al.
Publicado: (2022)

Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study
por: Ward, Elizabeth, et al.
Publicado: (2020)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
por: Yang, Benjamin Chi-Lan, et al.
Publicado: (2019)

Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy
por: Chen, Yu-Yen, et al.
Publicado: (2019)

Correlation between Macular Neovascularization (MNV) Type and Druse Type in Neovascular Age-Related Macular Degeneration (AMD) Based on the CONAN Classification
por: Muth, Daniel Rudolf, et al.
Publicado: (2022)

Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
por: Javidi, Simon, et al.
Publicado: (2020)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
por: Lin, Liang-Wei, et al.
Publicado: (2023)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
por: Seong, Hyo Jin, et al.
Publicado: (2022)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy
por: Delas, Barbara, et al.
Publicado: (2012)

Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
por: Reeves, Barnaby C, et al.
Publicado: (2011)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography
por: Shen, Mengxi, et al.
Publicado: (2023)

Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report
por: Nagai, Norihiro, et al.
Publicado: (2017)

Artificial Intelligence to Stratify Severity of Age-Related Macular Degeneration (AMD) and Predict Risk of Progression to Late AMD
por: Bhuiyan, Alauddin, et al.
Publicado: (2020)

A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vu3hj87vg81roprlnuct4tp14f